DXC
DXC Technology Co
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
News Summary
NegativeDXC is executing an aggressive AI-centric transformation with leadership overhaul and a strategic ElevenLabs partnership, but this is overshadowed by continued organic revenue decline (5-3% guidance), bookings weakness (down 18.5% YoY), and softening analyst price targets. The company faces a structural headwind in its legacy IT services business that near-term AI initiatives have not yet reversed.
Red flags
- •Organic revenue decline guidance of 3-5% for FY2027 with Q2 also expected to decline
- •Bookings declined 18.5% year-over-year, signaling weak customer demand and future revenue risk
- •Adjusted EBIT margin fell 30.6% year-over-year despite reported EBIT growth (suggesting one-time items or accounting adjustments masking operational pressure)
- •Analyst consensus price target reduced due to lower forward P/E multiple despite unchanged revenue growth expectations
- •FY2026 results missed organic revenue guidance by $75 million with bookings down 13.5% YoY, indicating execution gaps
- •Significant management turnover (GIS chief departure, multiple leadership changes) during period of operational decline raises stability concerns
Fund 13D/13G Filings (2)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).
| Fund | Form | ∆ Shares | % of Class | Since Filing | Filed | Src |
|---|---|---|---|---|---|---|
| Glenview Capital | SC 13G/A | −8.9M | 0.0% | +0.9% vs SPY -0.8% abs | 2026-08-14 | ↗ |
| Glenview Capital | SC 13G | NEW | 5.2% | — | 2026-03-27 | ↗ |